NCT06047379 2026-03-02Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.Phase 1/2 Recruiting134 enrolled
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT05941507 2025-09-24A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsLigaChem Biosciences, Inc.Phase 1/2 Recruiting300 enrolled
NCT02327078 2025-08-14A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)Incyte CorporationPhase 1/2 Completed307 enrolled 27 charts
NCT02611024 2025-07-09Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsPharmaMarPhase 1/2 Completed316 enrolled
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled
NCT01631552 2021-08-12Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerGilead SciencesPhase 1/2 Completed515 enrolled 28 charts 2 FDA